Preclinical Anti-infective Assets
Severe bacterial or fungal infections
PreclinicalIn portfolio
Key Facts
Indication
Severe bacterial or fungal infections
Phase
Preclinical
Status
In portfolio
Company
About Basilea Pharmaceutica
Founded in 2000, Basilea Pharmaceutica is a Swiss biopharma company dedicated to addressing the critical global health challenge of antimicrobial resistance. The company has successfully transitioned to a commercial-stage entity with two approved and marketed products, Cresemba and Zevtera, generating revenue and operating profit. With a focused pipeline, strategic collaborations like its BARDA partnership, and a commitment to ESG principles, Basilea is strategically positioned for growth in the specialized anti-infectives market.
View full company profileTherapeutic Areas
Other Severe bacterial or fungal infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Clinical Anti-infective Assets | Basilea Pharmaceutica | Clinical |